Evidence map›Paper›PMID 29089424›Full record

ArticlemBio2017

Evolved Aztreonam Resistance Is Multifactorial and Can Produce Hypervirulence in

Peter Jorth, Kathryn McLean, Anina Ratjen, Patrick R Secor, Gilbert E Bautista, Sumedha Ravishankar, Amir Rezayat, Jayanthi Garudathri, Joe J Harrison, Rachel A Harwood and 4 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 94 citations in OpenAlex.

  1. Article
  2. A genome-wide screen inJournal of bacteriology · 2026
    Article
  3. Article
  4. Article
  5. Metallo-β-lactamase-producingFrontiers in microbiology · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. A chronicInfection and immunity · 2025
    Article
  11. Addressing carbapenemase-producing extensively drug-resistant Pseudomonas aeruginosa: the potential of cefiderocol and ceftazidime/avibactam plus aztreonam therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Article
  12. Tracing the evolutionary trajectory of the IncP-2 plasmid co-harboringFrontiers in cellular and infection microbiology · 2025
    Article
  13. Article
  14. 7-Antibiotics (Basel, Switzerland) · 2024
    Article
  15. Article
  16. Antibiotics (Basel, Switzerland) · 2024
    Review
  17. Article
  18. Review
  19. Article
  20. Molecular analysis of metallo-beta-lactamase-producing Pseudomonas aeruginosa in Switzerland 2022-2023.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Peter JorthDepartment of Microbiology, University of Washington School of Medicine, Seattle, Washington, USA.
Kathryn McLeanDepartment of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Anina RatjenDepartment of Microbiology, University of Washington School of Medicine, Seattle, Washington, USA.
Patrick R SecorDepartment of Microbiology, University of Washington School of Medicine, Seattle, Washington, USA.
Gilbert E BautistaDepartment of Microbiology, University of Washington School of Medicine, Seattle, Washington, USA.
Sumedha RavishankarDepartment of Microbiology, University of Washington School of Medicine, Seattle, Washington, USA.
Amir RezayatDepartment of Microbiology, University of Washington School of Medicine, Seattle, Washington, USA.
Jayanthi GarudathriDepartment of Microbiology, University of Washington School of Medicine, Seattle, Washington, USA.
Joe J HarrisonDepartment of Biological Sciences, University of Calgary, Calgary, Alberta, Canada.
Rachel A HarwoodDepartment of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Kelsi PenewitDepartment of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Adam WaalkesDepartment of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Pradeep K SinghDepartment of Microbiology, University of Washington School of Medicine, Seattle, Washington, USA.
Stephen J SalipanteDepartment of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington, USA stevesal@uw.edu.
University of Washington · USUniversity of Calgary · CA

Funding

Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI PRADEEP k SINGH · 2010 to 2026
$21.4M
Studies on bacterial populations and therapeutics for CF lung infectionsK24HL102246 · NHLBI · UNIVERSITY OF WASHINGTON · PI SINGH, PRADEEP K · 2010 to 2019
$1.6M
NHLBI NIH HHS K24 HL102246NIDDK NIH HHS P30 DK089507
6 · The paper itself

Abstract

While much attention has been focused on acquired antibiotic resistance genes, chromosomal mutations may be most important in chronic infections where isolated, persistently infecting lineages experience repeated antibiotic exposure. Here, we used experimental evolution and whole-genome sequencing to investigate chromosomally encoded mutations causing aztreonam resistance in

Indexed as

Evolution, MolecularAnimalsAnti-Bacterial AgentsAztreonamChromosomes, BacterialChronic DiseaseCystic FibrosisDirected Molecular EvolutionDisease Models, AnimalDrug Resistance, Multiple, BacterialGenetic FitnessHumansMembrane Transport ProteinsMiceMicrobial Sensitivity TestsMutationAnti-Bacterial AgentsAztreonamMembrane Transport Proteinsantibiotic resistanceaztreonamcystic fibrosisfitnessPseudomonas aeruginosaselectionvirulencewhole-genome sequencing

Identifiers

PMID29089424
PMCPMC5666152
OpenAlexW2766544290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.